Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
PRCT Stock Chart & Stats
$32.73
-$0.85(-0.97%)
At close: 4:00 PM EST
$32.73
-$0.85(-0.97%)
Day’s Range― - ―
52-Week Range$27.80 - $89.49
Previous CloseN/A
Volume113.34K
Average Volume (3M)1.63M
Market Cap
$1.89B
Enterprise Value$1.77B
Total Cash (Recent Filing)$294.28M
Total Debt (Recent Filing)$78.93M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Mar 03, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding55,878,590
10 Day Avg. Volume1,723,968
30 Day Avg. Volume1,629,436
Financial Highlights & Ratios
PEG Ratio2.10
Price to Book (P/B)10.43
Price to Sales (P/S)18.70
P/FCF Ratio-40.50
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue5.91
Enterprise Value/Gross Profit9.16
Enterprise Value/Ebitda-23.43
Forecast
1Y Price Target
$51.75Price Target Upside58.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.51
Revenue Forecast (FY)$326.34M
Bulls Say, Bears Say
Bulls Say
Commercial ExecutionPRCT highlighted an increased focus on driving utilization through the implementation of several organizational changes and launching several initiatives aimed at improving commercial execution.
Market OpportunityThe core growth engine is fueled by increasing utilization in the existing installed base, with significant penetration opportunities in surgeries and hospitals.
Revenue GrowthQ3 revenue totaled $83.3M, up 43% from last year and comfortably ahead of the Street's $80.8M forecast.
Bears Say
Operational ExecutionPRCT has to show improved operational execution for confidence in FY26 numbers to improve.
Sales GuidancePRCT's stock is down 6% AH, likely in response to its decision to maintain its 2025 sales guidance and offer 2026 guidance that brackets the Street estimate at the high end.
Utilization ConcernsUtilization needs to improve, as physicians are only averaging ~1-2 procedures per month, which needs to increase to drive sustained handpiece growth.
PROCEPT BioRobotics News
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $27.80 and its highest was $89.49 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $1.89B.
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Mar 03, 2026 which is in 73 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Nov 04, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.412 by $0.032.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -0.32.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 55,878,590 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.412. Following the earnings report the stock price went down -9.737%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Currently, no hedge funds are holding shares in PRCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PROCEPT BioRobotics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.75 (58.11% Upside)
$51.75 (58.11% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 80%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 7.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.15%
12-Months-Change
Fundamentals
Return on Equity
-27.22%
Trailing 12-Months
Asset Growth
36.72%
Trailing 12-Months
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
PRCT Company Deck
PRCT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects strong revenue growth and significant increases in both U.S. and international sales, alongside positive gross margin expansion. However, persistent net losses, challenges in utilization growth, and anticipated procedural headwinds present concerns. The company remains optimistic about its strategic initiatives and long-term growth potential.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$51.75
▲(58.11% Upside)
Technical Analysis
Alphatec Holdings
―
Artivion
―
LivaNova
―
Inspire Medical Systems
―
SS Innovations International
―
Ownership Overview
3.04% Insiders
38.40% Mutual Funds
31.73% Other Institutional Investors
11.61% Public Companies and Individual Investors